Jane Hughes
Chief Tech/Sci/R&D Officer at GYROSCOPE THERAPEUTICS HOLDINGS PLC
Profile
Jane Hughes is currently the Chief Scientific Officer at Gyroscope Therapeutics Holdings Plc since 2019.
Prior to this, she worked as the Senior Director-Integrated Drug Discovery at Charles River Laboratories, Inc. from 2017 to 2018 and as the Director-Discovery Medicine & Immuno Inflammation at GSK Plc from 2014 to 2017.
She obtained a doctorate degree from Keele University.
Jane Hughes active positions
| Companies | Position | Start |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 2019-09-30 |
Former positions of Jane Hughes
| Companies | Position | End |
|---|---|---|
Charles River Laboratories, Inc.
 Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Charles River Laboratories, Inc. provides research models and laboratory animal support services. It offers quality research models and support services to the biomedical community. The company was founded in 1947 and is headquartered in Wilmington, MA. | Corporate Officer/Principal | 2018-10-31 |
| GSK PLC | Corporate Officer/Principal | 2017-05-31 |
Training of Jane Hughes
| Keele University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private companies | 2 |
|---|---|
Charles River Laboratories, Inc.
Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Charles River Laboratories, Inc. provides research models and laboratory animal support services. It offers quality research models and support services to the biomedical community. The company was founded in 1947 and is headquartered in Wilmington, MA. | Commercial Services |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Jane Hughes
